Ligasure and Conventional Diathermy Face Off in Hemorrhoidectomy Trial
A randomized trial at Sohag University is set to compare Ligasure with conventional diathermy in hemorrhoidectomy, a surgical question with immediate relevance in everyday colorectal practice. The study is built around a familiar surgical tradeoff: faster tissue sealing and potentially cleaner hemostasis on one side, versus a long-established electrocautery approach on the other. With symptomatic hemorrhoids as the target population, the trial is designed to measure what matters most at the bedside after surgery — bleeding, pain recovery, hospital stay, itching, and the pace at which patients return to normal life.
The study is interventional, randomized, and parallel in design, with single-participant masking. Enrollment is estimated at 40 patients, all of them symptomatic enough to require surgery. The population is intentionally narrow, excluding patients with other rectal or anal pathology, recurrent hemorrhoids, and medical or anesthetic contraindications. That makes the cohort clinically cleaner, although it also means the findings will speak first to straightforward operative candidates rather than to the broader and messier population seen in general practice.
Why Energy Choice Matters in Hemorrhoid Surgery
Hemorrhoidectomy is not only about removing tissue; it is also about controlling vascular injury in a region where postoperative bleeding, wound irritation, and delayed recovery can quickly affect the patient’s experience. The choice of energy device can influence how much thermal spread occurs, how well vessels are sealed, and how much secondary tissue injury follows the excision. Ligasure is being tested here as a device-based alternative to conventional diathermy, with the implication that more controlled vessel sealing may reduce bleeding and perhaps soften the postoperative course.
The trial’s primary outcome is bleeding at 2 days postoperatively. That timing is clinically meaningful because early bleeding after anorectal surgery can force urgent reassessment, prolong observation, or delay discharge. Secondary outcomes extend the lens to hospital stay at 4 days and postoperative itching at 2 weeks. Those measures may seem modest on paper, but in a condition where recovery is often measured in discomfort, sleep disruption, and fear of the next bowel movement, small differences can shape whether a procedure feels tolerable or punishing.
Study Design and Operative Comparison
Investigators are comparing two active arms: hemorrhoid treatment using Ligasure and hemorrhoid treatment using conventional diathermy. The study’s primary purpose is treatment, and the model is straightforward rather than exploratory. Both approaches are being used in excision of piles, but the record points specifically to Ligasure as the named device intervention, making the device-versus-standard-energy comparison the core of the protocol.
The sample size is small, and that matters for interpretation. A cohort of 40 can generate useful signal in a tightly defined surgical study, especially when the endpoints are immediate postoperative events rather than long-term recurrence or mortality. It cannot settle every question. Rare complications, subtle differences in wound healing, and patient-reported quality-of-life shifts may fall outside the statistical reach of such a sample, even if they are important in real-world use.
Still, the structure of the trial is sensible for a first comparison in this setting. Early bleeding is easy to define, hospital stay is operationally tangible, and itching two weeks after surgery captures a symptom patients actually remember. Those are practical outcomes for a surgical device study because they map closely to postoperative burden rather than to abstract surrogate metrics.
The patient-facing consequences are immediate. Less bleeding can mean fewer return visits, fewer anxieties about postoperative recovery, and less need for unplanned intervention. Shorter hospital stay can reduce disruption for patients and conserve inpatient resources. If itching is reduced, the wound may be healing in a way that is less irritating or less inflamed, though the record does not claim a mechanism and no mechanistic data are provided.
What the Protocol Reveals About Current Surgical Priorities
This trial also reflects how hemorrhoid surgery is being judged today. Success is no longer defined only by whether the excision is complete. Surgeons and patients both care about how the wound behaves afterward, how quickly function returns, and whether the operation creates a new problem while solving the original one. Bleeding, itching, and hospital time are not secondary inconveniences; they are the lived consequences of the procedure.
Because the study is still recruiting and no results are posted, there is no basis for claiming superiority of either technique. The record establishes a head-to-head comparison, not an outcome. It also shows that the sponsor is Sohag University and that the study is being conducted in Sohag, Egypt, with recruitment underway. Those details matter mainly because they situate the work in a real surgical setting rather than in a hypothetical device discussion.
The exclusion of recurrent hemorrhoids is clinically important. Recurrent disease often carries more scar tissue, altered anatomy, and a less predictable operative field, all of which can confound bleeding and recovery outcomes. By excluding those cases, the study tries to isolate the effect of the energy platform itself. That improves internal clarity, but it may also narrow the applicability of any eventual result to first-time or otherwise uncomplicated surgical candidates.
The Missing Piece Will Be the Postoperative Data
At this stage, the most important fact is also the most basic one: this is a protocol, not a results report. The study has a clear comparison, a defined endpoint structure, and a small but focused enrollment target. What it does not yet have is the evidence that will tell clinicians whether Ligasure truly changes early bleeding, shortens stay, or reduces postoperative itching compared with conventional diathermy.
When those data arrive, they will need to be interpreted with caution because the trial is modest in size and limited to a specific surgical population. For now, the protocol signals an effort to refine a common operation around outcomes patients feel quickly and remember clearly. In hemorrhoidectomy, that is often where the real difference is made — not in the excision itself, but in the recovery that follows.